News

Singapore
Angsana’s RNA-based fusions cancer panel selected for Ignyta’s STARTRK2 clinical trial in Asia-Pacific
Mar. 03, 2017.

Angsana Molecular & Diagnostics has announced today that it will be a partner molecular test lab for STARTRK-2 clinical trial sites in Asia working with Ignyta, Inc., (NASDAQ: RXDX), a biotechnology company focused on precision medicine in oncology. Angsana Molecular & Diagnostics’ fusion cancer panel will be used for screening TRK, ROS1 and ALK fusions in the STARTRK-2 clinical trial, a registration-enabling global Phase 2 basket clinical trial for entrectinib, Ignyta’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions.

 

Phase 1 data recently published online in Cancer Discovery showed entrectinib to be well tolerated, with responses observed in non-small cell lung cancer (NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma and renal cell carcinoma as early as four weeks after first treatment and lasting as long as 2.5 years and still ongoing. That publication reported a 79% response rate in 24 patients with TRK, ROS1, or ALK-driven extracranial solid tumors, and showed entrectinib responses to be both rapid and durable in patients with advanced solid tumors across multiple histologies and each of the molecular targets of interest, including in multiple patients with metastatic CNS disease.

 

“Ignyta is excited to partner with Angsana to conduct diagnostic screening at our STARTRK-2 clinical trial sites in Asia, which will help us get entrectinib to patients with tumors driven by TRK, ROS1 or ALK fusions,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “Entrectinib is the only TRK inhibitor to have published data demonstrating RECIST responses in NSCLC and in patients with cancer in the CNS. The anti-tumor activity seen across cancer types and entrectinib’s ability to treat bulky CNS disease, particularly important given the propensity for many solid tumors to metastasize to the brain, is extremely encouraging,” continued Dr. Lim.

 

“The era of the shift away from one-size-fits-all, trial-and-error medicine and toward a health care system that utilizes molecular information to improve outcomes and make the health care system more efficient has finally arrived to Asia Pacific especially in the area of targeted therapy in oncology,” says Dr Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. Dr Chris Tan added that our CAP accredited molecular lab, turnaround time and cost efficiency is critical to support Ignyta for their STARTRK-2 trial in Singapore and Asia.

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

 

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class or best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations. For more information, please visit: www.ignyta.com.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Gerard Yeong
[email protected]

Share
Singapore
EUROIMMUN (SEA) Partners with Angsana Molecular & Diagnostics on Allergy Diagnostics and Testing in Singapore
Nov. 22, 2016.

EUROIMMUN (SEA) and Angsana Molecular & Diagnostics today build a strategic partnership on the allergy diagnostics and testing to support clinicians, hospitals and private laboratories in South East Asia. This collaboration helps to bring the diagnostics and patient care synergies towards a better clinical management of patients with suspected allergies. Under the strategic collaboration, Angsana Molecular & Diagnostics would offer the comprehensive analysis of sensitizations against inhalation, food and other allergens to provide the precise determination of allergen. EUROIMMUN is committed with the customized two Allergy profiles to be well suited and cater to the region.

 

“There is a need for greater understanding on the risk of true poly-sensitizations for better patient management. With the simultaneous multi-parameter screening, the cooperation with EUROIMMUN gives us perfect position to take lead in allergy diagnostics and testing in the SEA region.” says Dr Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. Dr Chris Tan added that “This partnership enables us to combine cost effective and accurate health screening providing an expanded, high-quality diagnostics service under the CAP-accredited environment”.

 

 

The significance of this cooperation and contribution from both partners are recognized by Li Chuan, President of APAC Group and Managing Director of EUROIMMUN (SEA) Pte Ltd. “Our collaboration with Angsana Diagnostics will provide a precise determination for Allergy diagnostics to benefit the patients with suspected allergies. Furthermore, EUROIMMUN is committed to promote and focus on the use of allergy testing via EUROIMMUN Academy as continuous medical education to the clinicians and others.”

 

 

As a leading company in medical diagnostics, the cooperation between EUROIMMUN and Angsana Molecular & Diagnostics will play an important role in promoting the importance of diagnostics in the Asia Pacific region. Chief Executive Officer and Founder of EUROIMMUN Medizinische Labordiagnostika AG, Prof. Dr. Winfried Stöcker emphasized that “Asia Pacific region has been one of the important market for EUROIMMUN and we will continue to support the diagnostics market growth and development in Asia and EUROIMMUN, will and strive to enhance our collaboration with clinicians, medical providers to improve health outcomes and provide precise patient management.”

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About EUROIMMUN

EUROIMMUN was founded in 1987 and has its headquarters in Lübeck, Germany. It is committed to develop, produce and sell test systems for the diagnosis of diseases, and software and automation solutions for the performance and evaluation of these assays. So far laboratories in about 200 countries use EUROIMMUN products for the diagnosis of autoimmune, infectious diseases and allergies, and to perform genetic analyses. The company is based on worldwide-patented state-of-the-art production methods and microanalysis techniques and is one of the world’s leading manufacturers of medical laboratory diagnostics. The company’s reference laboratory is unequalled in the whole field of autoimmune diagnostics. With their quality and standardization, EUROIMMUN products are conquering the leading position in medical diagnostics worldwide. For more information, visit http://www.euroimmun.com.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Clara Fu
+852 2793 0782
[email protected]

Share
Singapore
Angsana Provides Tests for Allergen Sensitization Specific for Asian Population
Nov. 1, 2016.

Angsana Molecular & Diagnostics Laboratory today announced that it will provide tests for allergen sensitization specific for the Asian population using industry leading technology by Thermo Fisher Scientific. The tests will be based on Thermo Fisher’s ImmunoCAP technology and performed on Phadia Laboratory Systems.

 

Allergy constitutes a major health concern in both adolescents and adults. While many allergens are common across populations, there has been increased recognition of differences in the prevalence and morbidity of atopic diseases among different ethnic groups and across different geographic regions. Factors such as genetics, environmental exposure, diet and social behavior appear to contribute.

 

Angsana is seeking to define and validate specific tests for allergen sensitization that are suited to local needs. ImmunoCAP technology is well known for its high specificity and sensitivity, quantitative results, high quality and a comprehensive menu of allergens and allergen components. ”

 

Angsana is committed to deliver high-performance and affordable molecular diagnostic services to meet the health demand of Asian population. We are excited to work with Thermo Fisher and its technology to help us expand our service capabilities to better address this major public health concern,” said Dr. Chris Tan, Chief Executive Officer of Angsana. “With the rising incidence of atopic diseases, particularly among younger children, it is important to better understand the regional and ethnic differences in Asian countries,” said Dr. Richard Choy, Angsana’s Chief Scientific Officer and managing director of Angsana Hong Kong laboratory. “Through collaboration with local medical experts and healthcare providers, Angsana aims to provide a testing solution for Asia, in order to help improve the diagnosis efficiency and aid better allergy management.”

 

“We’re pleased that Angsana recognizes our quality and expertise and we are pleased that our technology can be used to support their efforts,” said [Stefan Wolf], president, ImmunoDiagnostics, Thermo Fisher. “Providing tests for allergen sensitization for the Asian population will help to enable healthcare professionals to have a better understanding of the symptoms of their patients.”

 

Angsana has recently acquired Allergy Laboratory, a Singapore-based private laboratory with over 10-year experience serving in the allergy testing business. “The acquisition enables us to combine the existing tests and dedicated expertise from Allergy Laboratory with the range of premium molecular assays from Angsana, providing an expanded, high-quality diagnostic services under the CAP-accredited environment” said Dr. Chris Tan from Angsana.

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Clara Fu
+852 2793 0782
[email protected]

Share
Singapore
Agilent Technologies Provides Tools to Angsana to Develop Molecular Assays to Improve Fetal and Maternal Health in Asian Population
Oct. 7, 2015.

Agilent Technologies Inc. (NYSE: A) today announced that it will provide genomic tools to Angsana Molecular & Diagnostics Laboratory, a multisite molecular diagnostics service provider headquartered in Singapore, to supply genomics products to enable Angsana to develop new genomics-based assays that are customized to fit the Asian population.

 

This collaboration enables Angsana to develop molecular diagnostics to create new solutions focused on fetal and maternal health.

 

To develop the assays, Angsana will use a range of Agilent technologies, including DNA microarrays, target enrichment platforms, DNA/RNA quality control tools, automated liquid handling, and probes that incorporate fluorescence in situ hybridization, or FISH, a technique used to detect the presence of specific DNA sequences.

 

“Agilent’s cutting-edge genomics technology enables precise identification of genetic changes,” said Russell McInnes, Agilent’s director of sales for genomics in the Southern Asia Pacific and Korea. “We are delighted to partner with Angsana as they develop new molecular assays relevant to local populations.”

 

“Angsana aims to be a life care company committed to better health care through providing trusted and high-quality molecular diagnostics services to the regional health-care network in Asia,” said Dr. Chris Tan, chief executive of Angsana. “Partnership with Agilent allows us to capture the best offered by the technology and to stay ahead of the competition.”

 

“About 2 to 3 percent of babies are born with some type of birth defect, many of which are due to chromosomal abnormalities,” said Dr. Richard Choy, Angsana’s chief scientific officer and managing director of the CAP-accredited Angsana Hong Kong Laboratory. “Technologies like the microarrays and target enrichment-based sequencing offered by Agilent provide the means to enable us to analyze genetic information in a fast, accurate and cost-effective manner. Through close collaboration with local maternal and fetal specialists, Angsana will be able to develop customized molecular assays validated for diagnosing chromosomal abnormalities in a fetus, providing expectant parents with a higher level of assurance.”

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.0 billion in fiscal 2014 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. Information about Agilent is available at www.agilent.com.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Hailing Sun
+65-6873-9959
[email protected]

 

Agilent Technologies Inc.
Victoria Wadsworth-Hansen
+1 408-553-2005
[email protected]

Share
Singapore
Establishment of Angsana Molecular & Diagnostics Pte Ltd
June 2014

MORE

Establishment of Angsana Molecular & Diagnostics Pte Ltd – a life care company committed to better healthcare for humanity’s tomorrow. Our headquarters is in Singapore with two other offices in Hong Kong and Malaysia. We specialize in developing premium genomic assays in four areas that have the largest impact on the Asian population – Molecular Oncology, Fetal Maternal Health, Allergy & Molecular Allergology as well as Pharmacogenomics.

Founded by a unique, diversified team of leading Asian Clinical Scientists, prominent Healthcare Leaders and Business Directors, we not only provide clinicians with the analysis of medical conditions at a molecular level but also consultation on the diagnosis.

 

To stay ahead in the field of molecular & diagnostics, we are backed by a world class Scientific Advisory Board comprising Medical and Clinical Geneticists from the US and Asia to help formulate our scientific research strategies as well as a research and development team with expertise in advanced genomic technologies and bioinformatics.

 

Partnerships with leading pharmaceutical and biotechnology companies as well as academic institutions in Asia and the US give us unique access to state-of-the-art technology and knowledge in molecular diagnostics.

 

We use advanced technology platforms such as Next-generation Sequencing, Microarray Platforms, Sanger Sequencing, Digital PCR and Real-time PCR, Karyotyping and FISH and Phadia Laboratory System, to generate genomic data that is then analysed by an established bioinformatics analysis system and seamlessly communicated to clinicians and patients through a secured Lab Information System via an online web portal.

 

With CAP accreditation and ISO 15189 certifications for laboratory facilities, we will be able to ensure the highest standards of service trusted by clinicians and patients.

 

singapore

Share